Business ❯ Pharmaceuticals ❯ Drug Development

Licensing Agreements

Zaltenibart Chronic Obstructive Pulmonary Disease (COPD) BioNTech International Licensing Glenmark Pharmaceuticals Immune-mediated Diseases Multiple Sclerosis Bofanglutide Heart Disease Partnerships International Partnerships China-Originated Drugs Cancer Treatments

4 ARTICLES

3d ago

Lilly Secures Global Rights to Hanmi’s Sonefpeglutide

The agreement gives Lilly exclusive development and commercial control outside Korea, with Hanmi taking a $75 million up‑front payment and large milestone and royalty upside.

3 ARTICLES

last mo.

JW Pharmaceutical Licenses Korean Rights to Gan & Lee’s GLP-1 Drug in Deal Worth Up to $81 Million

5 ARTICLES

6mo ago

Crescent, Kelun-Biotech Trade Cancer Asset Rights in Cross-Border Deal as Crescent Secures $185 Million

9 ARTICLES

7mo ago

Novo Nordisk Licenses Omeros’ MASP-3 Drug in Deal Worth Up to $2.1 Billion

8 ARTICLES

10mo ago

GSK Closes $12 Billion Licensing Pact for Hengrui’s COPD Therapy and 11 Preclinical Assets

4 ARTICLES

last yr.

Bristol Myers Squibb and BioNTech partner on $11 billion bispecific antibody cancer drug